Penwest Pharmaceuticals Co

Penwest Pharmaceuticals — Proxy Contest (June 2009)

34 slides from Penwest Pharmaceuticals's proxy contest presentation, Jun 5, 2009

  1. Slide 1: Focused Strategy to Drive Shareholder Value

    Focused Strategy to Drive Shareholder Value Jennifer Good President , CEO & Director June 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause the actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained he

  3. Slide 3: Information Concerning Participants

    Information Concerning Participants Information required to be disclosed with regard to the Company's directors, director nominees, officers and employees who, under the rules of the Securities and Exchange Commission (the "SEC"), are considered to be "participants" in the Company's solicitation of

  4. Slide 4: Who We Are & What We Do

    WHO WE ARE & WHAT WE DO a Ponwest

  5. Slide 5: Our Business

    Our Business Drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system A0001 is lead development asset. Also have rights to an additional NCE from Edison Also license our drug delivery technologies and

  6. Slide 6: 2009 Strategy

    2009 Strategy Focused strategy to drive shareholder value. The Company's plan for 2009 consists of the following key components: Maximize Opana revenues in partnership with Endo Advance A0001 to establish proof of concept for safety and efficacy Monetize the value of the Company's proven drug delive

  7. Slide 7: 2009 Value Drivers

    2009 Value Drivers We believe that by pursuing this strategy, we can enter 2010: As a profitable and cash flow positive Company Opana ER contributing at the full royalty rate Additional assets licensed to create incremental long term growth On a path towards demonstrating proof of concept around saf

  8. Slide 8: Opana ER

    Opana(r) ER Developed using Penwest's TIMERx technology Marketed by Endo Pharmaceuticals Indication: For the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time Endo's Opana ER Sales 1st Quarter Sales YTD Sales 2009 $ 4

  9. Slide 9: Opana ER Financials - U.S.

    Penwest receives a tiered royalty based upon annual U.S. net sales of Opana ER 22% up to $150m in sales 25%+ increasing in regular increments with net sales Top rate of 30% on sales Recorded $4.4m of royalty revenue for Q1 '09 Agreed to repay $28M in unfunded development costs through a temporary 50

  10. Slide 10: Opana ER ex-U.S.

    Worldwide rights ex-U.S. are jointly owned with Endo Economics to be shared 50/50 Penwest took the business development lead for Opana outside the U.S. in November 2008 Currently seeking licensees in several ex-U.S. territories; we believe a deal can be signed by the end of the first half of this ye

  11. Slide 11: Patents - Opana ER

    Patents - Opana ER Multiple generic filers in the U.S. Penwest and Endo have sued all generic filers First 30-month stay ends June 2010 Latest patent expires in 2013 Multiple additional clinical and formulation patent applications being prosecuted by Penwest and Endo. Beginning in late 2007, this cr

  12. Slide 12: A0001 Orphan Neurological Diseases

    Development of orphan drugs has risks, but is approachable for a small company: Receptive regulatory environment worldwide Reasonably sized clinical trials Marketing through specialty niche model A0001 Orphan Neurological Diseases Significant unmet medical need

  13. Slide 13: A0001 - Why We Think It Is Exciting

    A0001-Why We Think It Is Exciting... Compound is alpha-tocopherol quinone Co-enzyme Q class of drug. High dose co-enzyme Q supplementation is proven to have some effect in mitochondrial diseases. A0001 is significantly more bioavailable than co-enzyme Q Marketed in the 70's in France as a compound f

  14. Slide 14: 2009 A0001 Development Plan

    2009 A0001 Development Plan Commenced MAD dosing in Q2; data by end of June Commenced 6 month preclinical tox program; expect data by year end to enable clinical program in patients Initiate Phase IIa trial in H2 '09 with data expected in Q1 '10 The goal of these trials is to establish proof of conc

  15. Slide 15: TIMERx Technology

    TIMER«x Technology

  16. Slide 16: Drug Delivery Technology Licensing

    Pursuing technology licensing collaboration with companies utilizing our extended release technologies and formulation expertise Provides stability during the development of our own portfolio Leverages Company asset and capability Covers the salaries of approximately 8 people and a portion of our fi

  17. Slide 17: Goals for Drug Delivery - 2009

    Goals for Drug Delivery - 2009 Sign at least 2 additional deals. We expect that this business at least breaks even on a fully loaded basis with 2 deals a year Advance the 3 compounds currently under development to deliver the targeted formulations to collaborator Maintain upside on drugs from the ro

  18. Slide 18: Financially Solid - 2009 Guidance

    Financially Solid - 2009 Guidance 2009 Guidance 2008 Actual % Change Revenues $ 22 - 24m $ 8.5m 171% S,G &A 9 - 10m 12.1m (21)% R&D 12 - 14m 21.0m (38)% Net Loss $(1) - (3)m $( 26.7)m (93)% Q1 '09 opex was down 45% from Q1 '08 Improvement being driven by increased revenues and decreased operating ex

  19. Slide 19: Details of Cost Cutting Effort

    Details of Cost Cutting Effort Reduced headcount from 76 to 48 employees or 37% through 2 RIF's (Q1 '08 & Q1 '09) Reduced 2008 & 2009 salary increases, and executive officers took no increase in 2009 Narrowed the R&D portfolio to ensure adequate funding (nalbuphine on hold) Drug delivery collaborati

  20. Slide 20: Balance Sheet

    Balance Sheet Cash March 31, 2009 $ 15.0m Line of Credit at March 31, 2009 Repaid monthly through Sept 2010 $ 8.2m No capital required to execute business plan Current balance expected to bridge us to profitability No capital required to execute business plan Current balance expected to bridge us to

  21. Slide 21: Penwest 2009 Key Milestones

    Opana ER Increasing sales by our partner Endo Additional issued patents Ex-U.S. marketing collaborations with at least one signed by end H1 '09 A0001 Complete Phase Ib multiple ascending dose safety study in healthy volunteers with data by end of Q2 '09 Conduct long term preclinical tox program Init

  22. Slide 22: Opposing Strategy: Vote for Shareholder Value or Call It Quits

    Opposing Strategy Vote for Shareholder Value or Vote to Call It Quits Tang/Edelman Strategy: "...immediately winding down substantially all of the Company's operations..." Board unanimously disagrees for the following reasons: Leaves assets on the table which have not realized their full value (Opan

  23. Slide 23: Opposing Strategy: Risk of Losing NOLs

    Opposing Strategy Risk of losing access to the majority of our $91 million of available net operating loss tax carryforwards In 2008, Perceptive triggered a change in control under tax rules, which cost us access to $123 million of NOL's and an additional loss of $7 million in tax credits Under Sec

  24. Slide 24: Opposing Strategy: Risk of Losing NASDAQ Listing

    Opposing Strategy Risk of losing our NASDAQ listing because Penwest would be a "public shell" A public shell is defined as "A company with no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents..." Company would likely be delisted, impairing s

  25. Slide 25: A Simple Choice for Our Investors

    A Simple Choice for Our Investors: Build Shareholder Value or Call it Quits

  26. Slide 26: Why Are We Fighting?

    Why are We Fighting? Strongly believe narrowed strategy for 2009 is right one to build shareholder value in the short-term and prepare the Company for long-term growth Stopping now would prematurely cap potential upside for shareholders May even reduce the value through loss of access to tax credits

  27. Slide 27: Board Continuous Improvement

    Board Continuous Improvement Board Continuous Improvement - -Directors highlighted in red have been added since 2005 *Dates are as of annual meeting; 2009 assumes election of Company slate

  28. Slide 28: Highly Qualified Board Focused on Building Shareholder Value

    Highly Qualified Board Focused on Building Shareholder Value Since 2005, conscious effort to build a Board of experienced, skilled directors to match the Company's strategy If our nominees are elected, Board will reflect valuable combination of scientific, regulatory, medical, commercial, strategic

  29. Slide 29: Board Not Opposed to Considering Alternative Views

    Board Not Opposed to Considering Alternative Views Nomination of Joe Edelman reflects balanced, reasonable approach Dissident views will be represented in decision-making Facts about Edelman: Long-term Penwest shareholder Has previously offered constructive input about operations and R&D program Int

  30. Slide 30: Tang's Conduct Raises Serious Concerns

    Tang's Conduct Raises Serious Concerns Tang's conduct with Penwest raises serious concerns about his suitability to be a director Tang has twice offered in writing to give the Company's directors personally the A0001 asset and business opportunity for their own financial benefit without their having

  31. Slide 31: Penwest Board is Committed to Good Corporate Governance

    Penwest Board is Committed to Good Corporate Governance Penwest's Board is committed to good corporate governance and pay practices while protecting the interests of all shareholders Listens to Shareholders We have recommended that shareholders vote to elect as a director Joseph Edelman, a member of

  32. Slide 32: By-Law Amendments & Litigation = Seeking Immediate Control

    By-Law Amendments & Litigation= Seeking Immediate Control The Dissidents' proposals include: A resolution requesting that the Board immediately wind down substantially all of the Company's operations A resolution to amend the Company's by-laws to require approval of 75% or 81% of the directors for c

  33. Slide 33: Conclusion

    Conclusion Board unanimously believes that our strategy can build shareholder value in the short-term and prepare the Company for long-term growth by: Maximizing Opana revenues in partnership with Endo Advancing A0001 to establish proof of concept for safety and biological activity Monetizing the va

  34. Slide 34: Penwest

    AaFenwest (Nasdaq: PPCO) June 2009 aPenwest

Penwest Pharmaceuticals — Proxy Contest (June 2009) on 6ix